Gross Margin % is calculated as gross profit divided by its revenue. DMK Pharmaceuticals's Gross Profit for the
three
months ended in Sep. 2023 was $-0.33 Mil. DMK Pharmaceuticals's Revenue for the
three
months ended in Sep. 2023 was $0.01 Mil. Therefore, DMK Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2023 was -3,655.56%.
The historical rank and industry rank for DMK Pharmaceuticals's Gross Margin % or its related term are showing as below:
DMKPQ'
s Gross Margin % Range Over the Past 10 Years
Min: -211.09 Med: 25.02 Max: 43.24
Current: -37.27
During the past 13 years, the highestGross Margin % of DMK Pharmaceuticals was 43.24%. The lowest was -211.09%. And the median was 25.02%.
DMKPQ's Gross Margin % is ranked worse than 97.58% of 990
companies
in the Drug Manufacturers industry
Industry Median: 46.855
vs DMKPQ: -37.27
DMK Pharmaceuticals had a gross margin of -3,655.56% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for DMK Pharmaceuticals was 0.00% per year.
DMK Pharmaceuticals Gross Margin % Historical Data
The historical data trend for DMK Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DMK Pharmaceuticals Gross Margin % Distribution
For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where DMK Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
DMK Pharmaceuticals had a gross margin of -3,655.56% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
DMK Pharmaceuticals Gross Margin % Related Terms
Thank you for viewing the detailed overview of DMK Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DMKPQ has been successfully added to your 